LeonaBio, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark J. Litton
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 18706 North Creek Parkway Bothell WA United States of America 98011
- IPO Date
- Sep 18, 2020
- CIK
- 0001620463
- Website
- leonabio.com
- Similar Companies
- Business
- LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS). The company operates in the United States with headquarters in Bothell, Washington, and pursues a pipeline of oral small-molecule drug candidates across oncology and neurology. Main products and services - Drug discovery and development of small-molecule therapeutics across two core therapeutic areas: oncology (metastatic breast cancer) and neurodegenerative diseases (ALS and related conditions) - Lead drug candidates and preclinical/clinical-stage programs, including ATH-1105 and related small-molecule series designed to restore neuronal health and slow neurodegeneration - Preclinical research platforms and translational science support to advance candidate compounds into IND-enabling studies and early-phase clinical trials - Collaboration and strategic alliance activities with research institutions and biotechnology partners to accelerate development timelines - Regulatory planning and submission support for Phase I/II trials, including safety, pharmacology, and biomarker strategies - Intellectual property development and management for novel small-molecule compounds and related technologies - Corporate communications and investor relations activities to disclose program progress and strategic milestones Latest major company changes - Name change and ticker update to LeonaBio, Inc. in early 2026 as part of a strategic rebrand from Athira Pharma, signaling a clarified corporate focus and new governance structure - Initiation of or progression in Phase 1 clinical trials for lead candidates ATH-1105 and ATH-1020, with ongoing preclinical work for additional early compounds - Formation of new partnerships and potential strategic alliances to expand the drug discovery platform, enhance access to specialized scientific expertise, and accelerate entry into pivotal trials - Potential restructuring or organizational realignments corresponding to the rebranding, including updates to leadership roles and corporate strategy to reflect a broadened neuro-oncology and neurodegeneration pipeline - Geographic and operational adjustments aligning with the company’s transition, including expanded collaboration networks and potential facilities focusing on translational research and early-stage development Additional context - Industry: Biotechnology and pharmaceuticals; segments include clinical-stage drug development, small-molecule therapeutics, and translational science - Target markets/customers: biotechnology and pharmaceutical partners, academic and industry collaborators, patient communities through clinical development programs - Geographic operations: United States (headquarters in Bothell, WA); potential collaborations and trial sites domestically and internationally as programs advance - Founding year and headquarters: founded in the late 2000s under a prior corporate name; current headquarters located in Bothell, Washington - Subsidiaries/parent relations: rebranding aligned with Athira Pharma lineage; operating as LeonaBio, Inc. with potential corporate restructuring and updated governance Note: Information reflects recent public disclosures and industry reporting about LeonaBio, Inc. and its corporate evolution, including the name change and ongoing clinical programs, as of early 2026. For precise, up-to-date regulatory filings and program details, consult the company’s investor relations materials and primary regulatory disclosures.
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B.
LeonaBio, Inc. (LONA) Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene Transcript
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME)
Financial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)
Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN) Head to Head Analysis
Reviewing Athira Pharma (NASDAQ:LONA) & Liminatus Pharma (NASDAQ:LIMN)
Prime Medicine (NASDAQ:PRME) and Athira Pharma (NASDAQ:LONA) Head to Head Review
Financial Contrast: Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN)
Athira Pharma (NASDAQ:LONA) vs. Prime Medicine (NASDAQ:PRME) Financial Analysis
Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) Financial Review
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
ATHA Energy Announces USD$20 Million Convertible Debenture Financing
Queen's Road Capital Announces Investment in ATHA Energy Corp.
Athira Pharma (NASDAQ:ATHA) Insider Martin Javier San Sells 1,644 Shares of Stock
Athira Pharma (NASDAQ:ATHA) CEO Mark James Litton Sells 2,586 Shares